ADIPOQ and hyperprolactinemia: Compared to controls or patients with adequately treated hyperprolactinaemia, patients with hyperprolactinaemia have an adverse metabolic profile with higher levels of triglycerides, HOMA-IR (homeostatic model assessment – insulin resistance), lower adiponectin (de Assuncao Alves Rodrigues et al. 2012) and impaired glucose tolerance (Tourniaire et al. 1974), suggesting a diabetogenic effect of prolactin (Landgraf et al. 1977).